Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOTH NASDAQ:ORGS NASDAQ:PRPH NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOTHHoth Therapeutics$1.60$1.32$0.65▼$3.80$21.21M0.671.66 million shs2.77 million shsORGSOrgenesis$0.90-5.3%$0.65$0.00▼$6.40$4.32M3.196,764 shs100 shsPRPHProPhase Labs$0.43-15.8%$0.37$0.22▼$2.83$21.40M-0.782.41 million shs5.59 million shsTLPHTalphera$0.94-5.6%$0.51$0.38▼$1.20$20.44M-0.167.18 million shs1.74 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOTHHoth Therapeutics0.00%+20.30%+23.08%+23.08%+34.45%ORGSOrgenesis-5.26%+429.41%+3,990.91%-53.85%+89,999,900.00%PRPHProPhase Labs-15.84%+22.15%+32.41%+30.85%-83.94%TLPHTalphera-5.61%+71.16%+117.34%+88.00%+1.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOTHHoth Therapeutics$1.60$1.32$0.65▼$3.80$21.21M0.671.66 million shs2.77 million shsORGSOrgenesis$0.90-5.3%$0.65$0.00▼$6.40$4.32M3.196,764 shs100 shsPRPHProPhase Labs$0.43-15.8%$0.37$0.22▼$2.83$21.40M-0.782.41 million shs5.59 million shsTLPHTalphera$0.94-5.6%$0.51$0.38▼$1.20$20.44M-0.167.18 million shs1.74 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOTHHoth Therapeutics0.00%+20.30%+23.08%+23.08%+34.45%ORGSOrgenesis-5.26%+429.41%+3,990.91%-53.85%+89,999,900.00%PRPHProPhase Labs-15.84%+22.15%+32.41%+30.85%-83.94%TLPHTalphera-5.61%+71.16%+117.34%+88.00%+1.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOTHHoth Therapeutics 3.00Buy$4.00150.00% UpsideORGSOrgenesis 0.00N/AN/AN/APRPHProPhase Labs 0.00N/AN/AN/ATLPHTalphera 3.50Strong Buy$5.00431.91% UpsideCurrent Analyst Ratings BreakdownLatest ORGS, HOTH, PRPH, and TLPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/30/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/23/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/26/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/AORGSOrgenesis$662K6.52N/AN/A($6.58) per share-0.14PRPHProPhase Labs$6.77M2.66N/AN/A$0.25 per share1.73TLPHTalphera$650K29.68N/AN/A$0.47 per share2.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOTHHoth Therapeutics-$8.19M-$1.07N/AN/AN/AN/A-114.32%-105.92%11/11/2025 (Estimated)ORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%11/11/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-262.42%-76.48%11/12/2025 (Estimated)TLPHTalphera-$13M-$0.40N/AN/AN/AN/A-152.38%-64.32%11/12/2025 (Estimated)Latest ORGS, HOTH, PRPH, and TLPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TLPHTalphera-$0.1150-$0.10+$0.0150-$0.10N/AN/A8/13/2025Q2 2025PRPHProPhase Labs-$0.15-$0.11+$0.04-$0.11$3.55 million$1.25 million8/12/2025Q2 2025HOTHHoth Therapeutics-$0.27-$0.17+$0.10-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHOTHHoth TherapeuticsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOTHHoth TherapeuticsN/A27.5427.54ORGSOrgenesisN/A0.070.07PRPHProPhase Labs0.200.960.93TLPHTalpheraN/A2.932.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOTHHoth Therapeutics7.08%ORGSOrgenesis22.56%PRPHProPhase Labs9.45%TLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipHOTHHoth Therapeutics6.92%ORGSOrgenesis5.66%PRPHProPhase Labs9.60%TLPHTalphera3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOTHHoth Therapeutics413.26 million12.34 millionNot OptionableORGSOrgenesis1504.80 million4.53 millionNo DataPRPHProPhase Labs13041.54 million37.55 millionOptionableTLPHTalphera1920.52 million19.87 millionOptionableORGS, HOTH, PRPH, and TLPH HeadlinesRecent News About These CompaniesShort Interest in Talphera, Inc. (NASDAQ:TLPH) Rises By 1,945.8%September 12 at 4:14 AM | americanbankingnews.comCorMedix makes $5M minority equity investment in TalpheraSeptember 9, 2025 | msn.comTalphera, Inc. (NASDAQ:TLPH) Sees Significant Drop in Short InterestSeptember 9, 2025 | americanbankingnews.comCorMedix Announces Strategic Minority Investment in TalpheraSeptember 8, 2025 | globenewswire.comTalphera, Inc. Earnings Call Highlights Strategic ProgressAugust 31, 2025 | tipranks.comTalphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trialAugust 27, 2025 | finance.yahoo.comTalphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal TrialAugust 25, 2025 | prnewswire.comTalphera, Inc. (NASDAQ:TLPH) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | insidermonkey.comTalphera, Inc.: Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 15, 2025 | finanznachrichten.deTalphera Cuts Expenses 14 PercentAugust 15, 2025 | aol.comATalphera Reports Q2 2025 Financial Results and Study ProgressAugust 14, 2025 | tipranks.comTalphera, Inc. (TLPH) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comTalphera lowers 2025 cash operating expense view to $16M-$17M from $17M-$19MAugust 14, 2025 | msn.comTalphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | prnewswire.comA Preview Of Talphera's EarningsAugust 13, 2025 | benzinga.comTalphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025August 7, 2025 | prnewswire.comtalphera receives extension to meet nasdaq listing requirementsJune 7, 2025 | investing.comTalphera Granted Extension for Nasdaq ComplianceJune 5, 2025 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 17, 2025 | finanznachrichten.deEarnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025May 16, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025ORGS, HOTH, PRPH, and TLPH Company DescriptionsHoth Therapeutics NASDAQ:HOTH$1.60 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.61 +0.01 (+0.63%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Orgenesis NASDAQ:ORGS$0.90 -0.05 (-5.26%) As of 09/12/2025 10:21 AM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.ProPhase Labs NASDAQ:PRPH$0.43 -0.08 (-15.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.44 +0.01 (+1.73%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Talphera NASDAQ:TLPH$0.94 -0.06 (-5.61%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.94 0.00 (0.00%) As of 09/12/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
